ASCO: HER2-amplified biliary tract cancer responds to targeted treatment.
Health Medicine Network,
n nnn n n HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory…
n nnn n n HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory…
Source link : https://www.newshealth.biz/health-news/novel-anti-her2-drugs-64-in-95-biliary-cancer/ (*12*) CHICAGO — In a pair…